Stocks Intraday Alert - Venaxis Inc (NASDAQ:APPY), American Capital Ltd. (NASDAQ:ACAS), Keryx Biopharmaceuticals (NASDAQ:KERX), Kandi Technologies Group Inc (NASDAQ:KNDI)

Lewes, DE -- (SBWire) -- 09/07/2013 --LeadingStockAlerts is a financial marketing firm that specializes in assisting the underserved small cap and micro-cap stock community. Out Today’s Focus is on: Venaxis Inc (NASDAQ:APPY), American Capital Ltd. (NASDAQ:ACAS), Keryx Biopharmaceuticals (NASDAQ:KERX), Kandi Technologies Group Inc (NASDAQ:KNDI).

Venaxis Inc (NASDAQ:APPY) increased 3.07% and closed at $1.68 on a traded volume of 1.91 million shares, in comparison to 19.892 shares of average trading volume. So far this year, the stock is down over -36.6%.

The company has a total market capitalization of $36.04 million and its total outstanding shares are 21.45 million.

Will APPY Continue To Move Higher? Find Out Here

Venaxis, Inc. develops and commercializes products for unmet diagnostic and therapeutic needs. The company’s research and development activities primarily focus on a human acute appendicitis blood-based test.

American Capital Ltd. (NASDAQ:ACAS) soared 1.32% and closed at $13.05 on a traded volume of 1.90 million shares, whereas its average trading volume is 2.81 million shares. In the last three months, the stock is down -1.44%. The Intra-day range for the stock is $12.86 and $13.09.

Will ACAS Continue To Move Higher? Find Out Here

American Capital, Ltd. is a private equity and venture capital firm specializing in management and employee buyouts, leveraged finance, mezzanine, acquisition, recapitalization, middle market, and growth capital investments.

Keryx Biopharmaceuticals (NASDAQ:KERX) jumped 21.83% and closed at $9.32. So far in three months, the stock is up 21.83%. The 52-week range for the stock is $2.06 and $9.98 and during the previous trading session the stock touched its highest price at $9.45. Its introductory price for the day was $9.20, with the overall traded volume of 1.88 million shares.

Will KERX Continue To Move Higher? Find Out Here

Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment of renal disease in the United States.

Kandi Technologies Group Inc (NASDAQ:KNDI) after opening its trade at the price of $4.98, jumped 3.04% to close at $5.09 for the day. The stock moved on a traded volume of 1.85 million shares, in comparison to 1.02 million shares of average trading volume.

The 52-week range for the stock is $3.08 and $8.50 and during the previous trading session the stock touched its highest price at $5.34.

Will KNDI Continue To Move Higher? Find Out Here

Kandi Technologies Group, Inc., through its subsidiaries, engages in the design, development, manufacture, and commercialization of various vehicles.

About LeadingStockAlerts
LeadingStockAlerts is a financial marketing firm that specializes in assisting the underserved small cap and micro-cap stock community.

Our site has been the clear choice for today’s investors and day-traders. As one of the internet’s premiere financial destinations, we offer the investment community some of the market’s leading emerging opportunities. Using a balanced combination of industry experience and high-tech offerings, this site keeps you ahead of the curve and ahead of the bell.

Disclaimer
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT OR WEBSITE. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice.

The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice. The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

Read Full Disclaimer at: http://leadingstockalerts.com/disclaimer/

Media Relations Contact

News Department
http://leadingstockalerts.com/

View this press release online at: http://rwire.com/324525